Advaxis, Inc. (ADXS): Product News News

ADXS – Announces publication of data from study evaluating ADXS11-001 in combination with chemoradiation as a treatment for high-risk, locally advanced anal cancer in the International Journal of Radiation Oncology.

Key Facts Surrounding This News Item

  • ADXS had a POWR Rating of D (Sell) coming into today.
  • ADXS was 2.26% above its 10-Day Moving Average coming into today.
  • ADXS was 1.59% above its 20-Day Moving Average coming into today.
  • ADXS was -0.13% below its 50-Day Moving Average coming into today.
  • ADXS was -19.13% below its 100-Day Moving Average coming into today.
  • ADXS was -44.92% below its 200-Day Moving Average coming into today.
  • ADXS had returned +6.69% year-to-date leading up to today’s news, versus a +6.12% return from the benchmark S&P 500 during the same period.

More Info About Advaxis, Inc. (ADXS)

Advaxis Inc. is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary Lm Technology. The company was founded in 2002 and is based in Princeton, New Jersey. View our full ADXS ticker page with ratings, news, and more.

Try Premium Today!

Get access to our daily newsletters, Best Stocks List, POWR Ratings, and much more!
Free for 14 days -- no credit card required!

Sign Up Now

ADXS at a Glance

ADXS Current POWR Rating™
Overall POWR Rating™
ADXS Current Price $0.77 3.25%
More ADXS Ratings, Data, and News

ADXS Price Reaction

The day of this event (Jan. 25, 2018)
ADXS Closing Price$3.18 4.95%
ADXS Volume1,796,700
151.69% from avg
Leading up to this event
ADXS 1-mo returnN/A%
After this event
ADXS 1-day return2.71%
ADXS 3-day return0.00%
ADXS 5-day return3.41%

ADXS Price Chart

More Advaxis, Inc. (ADXS) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All ADXS News
Page generated in 1.1415 seconds.